PTX 0.00% 4.0¢ prescient therapeutics limited

Ann: PTX Receives Two US Patents Covering PTX-200, page-10

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 10,429 Posts.
    lightbulb Created with Sketch. 1155
    Quote from announcement - "Prescient CEO and Managing Director, Steven Yatomi-Clarke said, “We are very pleased with the overall progress of PTX-200. Early clinical data has been strong and underlines the potential of PTX-200 as a unique targeted therapy. The allowance of two additional US patents for PTX-200 is another important step in building out a strong product pipeline of novel personalised therapies for cancer. Prescient’s pipeline has never been stronger, nor deeper.”
 
watchlist Created with Sketch. Add PTX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.